NRSN

NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

About NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Details

Daily high
$1.24
Daily low
$1.09
Price at open
$1.22
52 Week High
$2.33
52 Week Low
$0.40
Market cap
22.0M
Dividend yield
0.00%
Volume
263,292
Avg. volume
143,318
P/E ratio
-2.12

NeuroSense Therapeutics Ltd. Ordinary Shares News

Details

Daily high
$1.24
Daily low
$1.09
Price at open
$1.22
52 Week High
$2.33
52 Week Low
$0.40
Market cap
22.0M
Dividend yield
0.00%
Volume
263,292
Avg. volume
143,318
P/E ratio
-2.12